Takeda and Enterome collaborate on new therapeutics for stomach disorders
pharmafile | January 6, 2016 | News story | Research and Development | Enterome, Takeda, gastrointestinal, inflammatory bowel syndrome, irritable bowel syndrome
Takeda and Enterome Bioscience have entered a drug discovery collaboration to research and develop potential new therapeutics for disorders including inflammatory and irritable bowel syndrome.
Enterome will use its proprietary metagenomic platform to support the discovery of potential novel agents (either small molecules or biologics) derived from gut bacteria and directed to gastrointestinal targets selected by Enterome and Takeda. Takeda has an option to develop and commercialise potential agents to emerge from the collaboration on an exclusive global basis.
In return, Enterome will receive an undisclosed upfront payment and three-year R&D funding, and is eligible to receive additional payments for each molecule discovered through the collaboration in the form of option exercise, development, regulatory and commercial milestone payments. In addition, Enterome – founded in Paris in 2012 – is eligible to receive potential tiered royalties on the net sales of any products that are commercialised by Takeda.
“This strategic collaboration with Takeda is a significant achievement for Enterome and represents an important step towards realising the full potential of our expertise and unique capabilities in unlocking the microbiome to generate new therapeutic solutions to serious diseases,” comments Pierre Belichard, chief executive of Enterome.
“We are delighted to begin this new collaboration, which will combine our continuing leadership in the microbiome space and Takeda’s global therapeutic drug discovery and development capabilities. It is also an important step for Enterome towards achieving its ambition to become a leading global biopharmaceutical company in the microbiome space.”
Gareth Hicks, head of gastroenterology drug discovery for Takeda, adds: “In partnering with scientists at Enterome, who perform cutting-edge research into microbiome-derived agents, Takeda is able to explore this exciting science and bring innovative therapies forward.”
Joel Levy
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
